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ABSTRACT
The most common T-serotypes among group A
streptococci (n = 88) isolated from pharyngeal
samples of children referred to a tertiary hospital
in Cyprus for pharyngitis or scarlet fever during a
14-month period (2003–2004) were T28 (25%),
T8 ⁄ 25 ⁄ Imp19 (22.7%) and T12 (9.1%). All 88
isolates were sensitive to penicillin and clinda-
mycin, but 1.1% and 18.2% of isolates were
resistant to erythromycin and tetracycline,
respectively. Macrolide consumption was estima-
ted at 1.7 deﬁned daily doses ⁄ 1000 inhabit-
ants ⁄day. The low percentage of resistance to
macrolides may have been related, at least in part,
to the low consumption of macrolides.
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Streptococcus pyogenes (group A streptococcus;
GAS) is a bacterial pathogen that causes diverse
diseases, ranging from superﬁcial to serious
invasive infections [1,2]. Characterisation of GAS
is classically based on the identiﬁcation of T and
M cell-wall protein antigens, and detection of the
serum opacity factor [3]. Detection of the M
protein, or the emm gene encoding the M protein,
is an important part of GAS characterisation, as
the M protein represents a major and very
important virulence factor [4]. T-typing and opa-
city factor determination are useful in clinical
situations where the number of GAS types is
limited, and represent useful supplements to
M ⁄ emm-typing [3,5]. The simplicity and cost-
effectiveness of T-typing have established this
method as the ﬁrst step for screening GAS
isolates.
Penicillin continues to be the drug of choice for
superﬁcial GAS infections, with erythromycin
also being used as an alternative treatment [6].
Despite GAS exhibiting sensitivity to b-lactam
antibiotics, resistance to macrolides has been
increasing in many countries, ranging from 6.2%
in North America to >20% in some European
countries, e.g., Spain and Greece [7–9].
Data concerning the epidemiology of GAS
infections in Cyprus are limited. The present study
describes the characterisation of GAS isolates from
pharyngeal infections in children, including their
sensitivity to penicillin, erythromycin, clindamy-
cin and tetracycline. The study was conducted at
the Archbishop Makarios Hospital (AMH), Nico-
sia, Cyprus, which is a tertiary 250-bed healthcare
facility. The catchment area of the hospital is
estimated to include c. 300 000 individuals (Nico-
sia district); in addition, some patients are referred
from other districts, since AMH is considered to be
a main paediatric referral centre.
GAS strains were isolated from pharyngeal
swabs of all paediatric patients who visited the
outpatient department or were admitted to the
hospital between 1 November 2003 and 31 Decem-
ber 2004 with throat infections. Isolates were
identiﬁed as S. pyogenes by colony morphology,
b-haemolysis and sensitivity to bacitracin 0.1 IU
(Abtek Biologicals, Liverpool, UK), and were
conﬁrmed as Lanceﬁeld Group A by latex agglu-
tination grouping. T-typing was performed using
the slide agglutination method with rabbit anti-T
sera (Sevapharma, Praha, Cech Republic), while
the serum opacity factor was determined using the
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agar method with sterile ﬁltered horse serum (TCS
Biosciences, Buckingham, UK) as described previ-
ously [3].
All GAS isolates were tested by the disk-
diffusion method for their sensitivity to penicillin,
tetracycline, erythromycin and clindamycin.
MICs were determined by Etest (AB Biodisk
Solna, Sweden) for isolates that showed resistance
to any of the antibiotics tested. The three eryth-
romycin resistance phenotypes were differenti-
ated by the double-disk test, using erythromycin
and clindamycin disks as described previously
[10]. Culture conditions, as well as interpretation
of the inhibition zones and MICs, were according
to CLSI criteria.
Information concerning consumption of antibi-
otics in Cyprus was provided by the Pharmaceu-
tical Service of the Cypriot Ministry of Health.
Data were collected using anatomical therapeutic
classiﬁcation ⁄daily deﬁned doses (ATC ⁄DDD)
methodology, with results expressed in
DDD ⁄ 1000 inhabitants ⁄day (DID).
During the study period, 88 GAS isolates were
obtained from 88 children (aged 9 months to
15 years; mean age 6.6 years) presenting with
pharyngitis or scarlet fever. Forty-six of the
children were males and 42 were females.
Table 1 summarises the T-types and the antibi-
otic sensitivity patterns for the isolates. Only one
(1.1%) GAS isolate was resistant to erythromycin
(M-phenotype). No resistance to either penicillin
or clindamycin was detected. However, 16
(18.2%) GAS isolates were resistant to tetracyc-
line, with MICs ranging from 12 to 48 mg ⁄L.
Macrolide consumption in Cyprus was estimated
to be 1.7 DID.
To the best of our knowledge, this is the ﬁrst
published study describing the circulating
T-serotypes and antimicrobial resistance patterns
of S. pyogenes isolates from Cyprus. A diverse
population of GAS serotypes was revealed, to-
gether with a low frequency of erythromycin
resistance (1.1%) and a much higher frequency of
tetracycline resistance (18.2%). Of the 88 GAS
isolates, 86 (97.7%) were T-typeable, which is a
high ﬁgure in comparison with other countries,
e.g., Greece (96%), the USA (89%), Thailand (60%)
and Malaysia (40%) [11–13]. Eleven T-serotypes
were detected during the study, the most common
of which was T28. A similar diversity among T-
serotypes was revealed in a study undertaken in
Athens, Greece, where 36 different T-types were
isolated over a 3-year period [11].
Resistance to erythromycin (1.1%) appeared to
be one of the lowest levels in Europe and
worldwide, with other studies reporting frequen-
cies of 6% in France, 3–7% in the USA, 5–24% in
Greece, 25-> 30% in Italy, and 22% in Spain
[7–9,11,14–16].
Several limitations of the present study should
be acknowledged. Most importantly, there was a
limited number of GAS isolates, and M ⁄ emm-
typing was not performed. Nevertheless, the
results obtained were similar to those reported
from other European countries with respect to the
diversity among T-serotypes. The low level of
macrolide resistance may be related to the low
consumption of macrolides in Cyprus during the
study period compared with other European
countries [17]. Reports from several countries have
correlated decreased consumption of antibiotics
with reduced resistance, or vice versa [18–20].
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Table 1. T-serotypes and erythromycin and tetracycline
susceptibility of group A streptococci isolated from paedi-











28 + 20 0 2 22
8 ⁄ 25 ⁄ Imp19 + 19 0 1 20
12 – 3 0 5 8
3 – 7 0 0 7
12 + 0 0 6 6
25 + 6 0 0 6
1 – 5 0 0 5
3 ⁄ 13 ⁄B3264 – 4 0 0 4
B3264 + 1 0 1 2
6 – 2 0 0 2
3 ⁄ 13 ⁄B3264 + 1 0 0 1
13 + 0 0 1 1
25 – 1 0 0 1
14 + 1 0 0 1
Non-typeable – 0 1 0 1
Non-typeable + 1 0 0 1
Total 71 1 16 88
OF, opacity factor.
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